Evidence map›Paper›PMID 36574911›Full record

ArticleUrology2023

Natural History of Multiple Recurrences in Intermediate-Risk Non-Muscle Invasive Bladder Cancer: Lessons From a Prospective Cohort.

Vidit Sharma, Karim Chamie, Mark Schoenberg, Valerie S Lee, Katherine Fero, Patrick Lec, Julie R Munneke, David S Aaronson, Lawrence H Kushi, Charles P Quesenberry and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Vidit SharmaDepartment of Urology, University of California Los Angeles, Los Angeles, CA; Department of Urology, Mayo Clinic, Rochester, MN.
Karim ChamieDepartment of Urology, University of California Los Angeles, Los Angeles, CA.
Mark SchoenbergDepartment of Urology, The Albert Einstein College of Medicine, Bronx, NY.
Valerie S LeeDivision of Research, Kaiser Permanente Northern California, Oakland, CA.
Katherine FeroDepartment of Urology, University of California Los Angeles, Los Angeles, CA.
Patrick LecDepartment of Urology, University of California Los Angeles, Los Angeles, CA.
Julie R MunnekeDivision of Research, Kaiser Permanente Northern California, Oakland, CA.
David S AaronsonDepartment of Urology, Kaiser Permanente Oakland Medical Center, Oakland, CA.
Lawrence H KushiDivision of Research, Kaiser Permanente Northern California, Oakland, CA.
Charles P QuesenberryDivision of Research, Kaiser Permanente Northern California, Oakland, CA.
Li TangDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Marilyn L KwanDivision of Research, Kaiser Permanente Northern California, Oakland, CA. Electronic address: Marilyn.L.Kwan@kp.org.
Kaiser Permanente · USUniversity of California, Los Angeles · USAlbert Einstein College of Medicine · USKaiser Permanente Oakland Medical Center · USRoswell Park Comprehensive Cancer Center · US

Funding

Diet and Lifestyle in a Prospective Study of Bladder Cancer SurvivorsR01CA172855 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI KUSHI, LAWRENCE H, KWAN, MARILYN L · 2014 to 2018
$5.0M
NCI NIH HHS R01 CA172855
6 · The paper itself

Abstract

objectiveTo describe the risk of multiple recurrences in intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC) and their impact on progression. Prognostic studies of IR-NMIBC have focused on initial recurrences, yet little is known about subsequent recurrences and their impact on progression. MATERIALS AND

methodsIR-NMIBC patients from the Be-Well Study, a prospective cohort study of NMIBC patients diagnosed from 2015 to 2019 at Kaiser Permanente Northern California, were identified. The frequency of first, second, and third intravesical recurrences of urothelial carcinoma were characterized using conditional Kaplan-Meier analyses and random-effects shared-frailty models. The association of multiple recurrences with progression was examined.

resultsIn 291 patients with IR-NMIBC (median follow-up 38 months), the 5-year risk of initial recurrence was 54.4%. After initial recurrence (n = 137), 60.1% of patients had a second recurrence by 2 years. After second recurrence (n = 70), 51.5% of patients had a third recurrence by 3 years. In multivariable analysis, female sex (Hazard Ratio 1.51, P< .01), increasing tumor size (HR 1.14, P< .01) and number of prior recurrences (HR 1.24, P< .01) were associated with multiple recurrences; whereas maintenance BCG (HR 0.66, P = .03) was associated with reduced recurrences. The 5-year risk of progression varied significantly (P< .01) by number of recurrences: 9.5%, 21.9%, and 37.9% for patients with 1, 2, and 3+ recurrences, respectively.

conclusionsMultiple recurrences are common in IR-NMIBC and are associated with progression. Female sex, larger tumors, number of prior recurrences, and lack of maintenance BCG were associated with multiple recurrences. Multiple recurrences may prove useful as a clinical trial endpoint for IR-NMIBC.

Indexed as

Carcinoma, Transitional CellNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsAdjuvants, ImmunologicAdministration, IntravesicalBCG VaccineDisease ProgressionFemaleHumansNeoplasm InvasivenessNeoplasm Recurrence, LocalProspective StudiesAdjuvants, ImmunologicBCG Vaccine

Identifiers

PMID36574911
PMCPMC12327494
OpenAlexW4312203658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.